Dmitry Nosov
Impact in
-
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 29
-
- Renal and related cancers 10
- Co-authors
- Rustem Gafanov (11 shared papers)V.P. Stus (10 shared papers)Elizabeth R. Plimack (10 shared papers)Bohuslav Melichar (10 shared papers)Thomas Powles (9 shared papers)Brian I. Rini (10 shared papers)Delphine Borchiellini (9 shared papers)Denis Soulières (9 shared papers)
- Journals
- Journal of Clinical Oncology (19 papers)The Lancet Oncology (2 papers)Frontiers in Oncology (1 paper)European Journal of Cancer (1 paper)Annals of Oncology (1 paper)
- Partner nations
- RussiaUnited StatesFrance
In The Last Decade
Dmitry Nosov
35 papers receiving 1.1k citations
Dmitry Nosov's Hit Papers
Peers
Comparison fields: 5 of 60
- Pulmonary and Respiratory Medicine 941
- Cancer Research 410
- Oncology 542
- Gastroenterology 64
- Molecular Biology 533
Countries citing papers authored by Dmitry Nosov
This map shows the geographic impact of Dmitry Nosov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitry Nosov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitry Nosov more than expected).
Fields of papers citing papers by Dmitry Nosov
This network shows the impact of papers produced by Dmitry Nosov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitry Nosov. The network helps show where Dmitry Nosov may publish in the future.
Co-authors
The 25 scholars most cited alongside Dmitry Nosov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2020 | 498 |
| 2 | 2012 | 86 | |
| 3 | 2019 | 86 | |
| 4 | 2015 | 80 | |
| 5 | 2021 | 75 | |
| 6 | 2012 | 69 | |
| 7 | 2020 | 46 | |
| 8 | 2023 | 45 | |
| 9 | 2018 | 34 | |
| 10 | 2009 | 25 | |
| 11 | 2013 | 21 | |
| 12 | 2019 | 11 | |
| 13 | 2011 | 10 | |
| 14 | 2013 | 10 | |
| 15 | 2013 | 9 | |
| 16 | 2024 | 8 | |
| 17 | 2021 | 8 | |
| 18 | 2021 | 5 | |
| 19 | 2022 | 4 | |
| 20 | 2013 | 4 |
About Dmitry Nosov
Dmitry Nosov is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Cancer Research and Surgery, having authored 40 papers that have together received 1.2k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (29 papers), Cancer Genomics and Diagnostics (11 papers), Renal and related cancers (10 papers), Cancer Immunotherapy and Biomarkers (10 papers), Economic and Financial Impacts of Cancer (6 papers), Bladder and Urothelial Cancer Treatments (5 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (941 citations), Cancer Research (410 citations), Oncology (542 citations), Gastroenterology (64 citations) and Molecular Biology (533 citations). Dmitry Nosov has collaborated with scholars based in Russia, United States and France. Frequent co-authors include Rustem Gafanov, V.P. Stus, Elizabeth R. Plimack, Bohuslav Melichar, Thomas Powles, Brian I. Rini, Delphine Borchiellini, Denis Soulières, Ihor Vynnychenko and Frédéric Pouliot. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology, Frontiers in Oncology, European Journal of Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.